The hypothetical cessation of all PSA testing for asymptomatic men in 2015 would result in a substantial decrease, RR 0.72 (95% MCI 0.72–0.73), of prostate cancer incidence compared with the current testing rates over 20 years as well as no overdiagnosis of asymptomatic men. Here, KLK3 is linked to prostate cancer.